Fig. 2From: Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case–control studyChanges in HbA1c (a), eGFR (b), and urinary albumin excretion (c). There were no significant differences in the levels of HbA1c, eGFR, and urinary albumin excretion between the sitagliptin and teneligliptin treatment groupsBack to article page